Biotech Values

[Bickema]

(RVNC) - BOTOX FOR THE MASSES: EVOLUS FILES FOR A $75 MILLION IPO

https://www.renaissancecapital.com/IPO-Center/News/54361/Botox-for-the-masses-Evolus-files-for-a-$75-million-IPO?utm_source=dlvr.it&utm_medium=stocktwits

https://www.evolus.com/

Guggenheim Downgrades Revance Therapeutic (RVNC) to Neutral

Guggenheim downgraded Revance Therapeutic (NASDAQ: RVNC) from Buy to Neutral.

Analyst Rohit Vanjani commented, "Revance reported RT002 phase 2a plantar fasciitis interim data, which showed improvement over placebo for pain at 8 weeks (the primary endpoint), but did not meet statistical significance. The company likely will re-run the phase 2a trial with a modified design following review of the full dataset (16 weeks). While Revance still potentially could get acquired, announce a business development transaction, or announce another therapeutic indication for RT002, we believe that there are too few visible catalysts in the intermediate term to move the shares. We move to a Neutral rating."

For an analyst ratings summary and ratings history on Revance Therapeutic click here. For more ratings news on Revance Therapeutic click here.

Shares of Revance Therapeutic closed at $33.20 yesterday.